AVNS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVNS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Avanos Medical's EBITDA per Share for the three months ended in Sep. 2024 was $0.52.
During the past 12 months, Avanos Medical's average EBITDA Per Share Growth Rate was 41.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Avanos Medical was 34.10% per year. The lowest was -53.10% per year. And the median was -11.80% per year.
For the Medical Devices subindustry, Avanos Medical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Avanos Medical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Avanos Medical's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Avanos Medical (NYSE:AVNS) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Thank you for viewing the detailed overview of Avanos Medical's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael Greiner | officer: SVP - Chief Financial Officer | C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421 |
Julie Ann Shimer | director | 18453 LAS CUMBRES ROAD, LOS GATOS CA 95033 |
Sudhakar Varshney | officer: SVP, Global Supply Chain | 5405 WINDWARD PARKWAY, SUITE 100 SOUTH, ALPHARETTA GA 30004 |
Lisa Egbuonu-davis | director | C/O OMEGA HEALTHCARE INVESTORS, INC., 303 INTERNATIONAL CIRCLE, SUITE 200, HUNT VALLEY MD 21030 |
John Joseph Hurley | officer: Principal Accounting Officer | 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004 |
Patrick J Oleary | director | 31515 BALLANTYNE CORP, C/O SPX CORP, CHARLOTTE NC 28277 |
Mojirade James | officer: SVP, General Counsel | 5405 WINDWARD PKWY, ALPHARETTA GA 30004 |
Kerr Holbrook | officer: SVP, GM Chronic Care | 5405 WINDWARD PKWY, ALPHARETTA GA 30004 |
William David Haydon | officer: SVP, GM Pain Franchise | 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004 |
David Edward Ball | officer: SVP - Global Supply Chain | AVANOS MEDICAL, INC., 5405 WINDWARD PKWY, ALPHARETTA GA 30004 |
Arjun Ranjan Sarker | officer: Senior VP, International | HALYARD HEALTH, INC., 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004 |
Gary Blackford | director | 7700 FRANCE AVENUE SOUTH, EDINA MN 55435 |
Joseph Fralin Woody | director, officer: Chief Executive Officer | 5405 WINDWARD PARKWAY, SUITE 100 SOUTH, ALPHARETTA GA 30004 |
Steven E Voskuil | officer: See Remarks | 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004 |
John W Wesley | director | 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004 |
From GuruFocus
By PRNewswire • 04-25-2024
By PRNewswire • 07-01-2024
By GuruFocus News • 11-14-2024
By GuruFocus Research • 02-28-2024
By PRNewswire • 05-13-2024
By GuruFocus Research • 02-20-2024
By GuruFocus News • 10-31-2024
By GuruFocus News • 10-30-2024
By PRNewswire • 11-05-2024
By PRNewswire • 07-31-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.